How to Apply for the Speciality Medicines Limited IPO: Step-by-Step Investment Guide

Summary:


Speciality Medicines Limited is a pharmaceutical distribution company engaged in supplying speciality formulations for chronic and complex conditions. The IPO is scheduled to open on 20 March 2026 and close on 24 March 2026. It comprises 23,50,000 shares with an issue size aggregating up to ₹29 crore. The price band is set between ₹117 and ₹124 per share, with a lot size of 1000 shares, and the shares are proposed to be listed on the BSE SME platform.

Speciality Medicines Limited operates in the pharmaceutical distribution segment, focusing on the marketing and supply of speciality formulations used in the treatment of chronic and complex conditions. The company provides products in various dosage forms, including tablets, injections, and inhalers, catering to different therapeutic requirements. Its operations are structured around contract manufacturing for international markets and the distribution of sourced pharmaceutical products within domestic regions. This approach places the company within the broader pharmaceutical supply chain, with exposure to both domestic and overseas markets. The business model includes collaboration with manufacturing partners and a distribution-focused structure, which may influence its positioning within the pharmaceutical market.

The application process for the IPO can be completed through the ASBA facility available via net banking or through a UPI-enabled trading platform. Investors are required to log in, select the IPO section, enter bid details such as the price band and lot size, and confirm the application by authorising the payment mandate. The application amount remains blocked in the bank account until the allotment process is completed, in accordance with applicable guidelines.

For more details, visit the Speciality Medicines Limited IPO page.

Speciality Medicines Limited IPO Details and Objectives

Details

Information

IPO Date

Mar 20, 2026 to Mar 24, 2026

Issue Size

23,50,000 shares (agg. up to ₹29 Cr)

Price Band

₹117 to ₹124 per share

Lot Size

1000 shares

Listing At

BSE SME

Market Maker

Aikyam Capital Private Limited

Purpose of the IPO

  • Setting up of Research and Development (R&D) Centre at Revenue City Survey No. RV1/NA/61/1/50, Moje, Manda, Tal. Umargam, Dist. Valsad, Gujarat
  • Product Registration in International Markets and Product Development for sale in international markets
  • Funding for Marketing and Promotional Activities
  • To Meet Working Capital Requirements
  • General corporate purposes

Timeline of Speciality Medicines Limited IPO

Event

Date

IPO Open Date

Fri, Mar 20, 2026

IPO Close Date

Tue, Mar 24, 2026

Tentative Allotment

Wed, Mar 25, 2026

Initiation of Refunds

Fri, Mar 27, 2026

Credit of Shares to Demat

Fri, Mar 27, 2026

Tentative Listing Date

Mon, Mar 30, 2026

Cut-off time for UPI mandate confirmation

5 PM on Tue, Mar 24, 2026

Pricing & Lot Size of Speciality Medicines Limited IPO

Price Band for the IPO

  • ₹117 to ₹124 per share

Minimum Lot Size and Application Details

Application

Lots

Shares

Amount

Individual investors (Retail) (Min)

2

2,000

₹2,48,000

Individual investors (Retail) (Max)

2

2,000

₹2,48,000

S-HNI (Min)

3

3,000

₹3,72,000

S-HNI (Max)

8

8,000

₹9,92,000

B-HNI (Min)

9

9,000

₹11,16,000

Speciality Medicines Limited IPO Application Process

The Speciality Medicines Limited IPO application process can be completed online through your trading platform. Below is a step-by-step guide to applying for the IPO:

Step 1: Login to Your Trading Platform

Access your trading account using the broker's app or website.

Step 2: Navigate to the IPO Section

Go to the IPO section to view active IPO listings.

Step 3: Select the Open IPO and Click Apply

Locate Speciality Medicines Limited IPO in the list of available IPOs and click the ‘Apply’ button.

Step 4: Enter the Quantity of Shares You Wish to Apply For

Specify the number of shares (lot size: 1000 shares) within the price band of ₹117 to ₹124 per share.

Step 5: Provide Your UPI ID

Enter your UPI ID for payment authorisation and ensure sufficient funds in your bank account.

Step 6: Confirm the Application

Review your application details and confirm the UPI mandate before 5 PM on the last application day.

Step 7: Complete the Process and Wait for Allotment

Submit the application and monitor the allotment status to check if shares have been allocated to you.

Shares Offered in Speciality Medicines IPO

The allocation of shares in the Speciality Medicines IPO is structured across investor categories in line with applicable regulatory requirements. The issue provides defined reservations for qualified institutional buyers, non-institutional investors, and retail individual investors, with each category allotted a specified proportion of the net issue. This allocation framework outlines how the shares offered are distributed among different classes of investors.

Investor Category

Shares Offered

QIB Shares Offered

Not more than 2% of the Net Issue

Retail Shares Offered

Not less than 49% of Net Issue

NII Shares Offered

Not less than 49% of Net Issue

This reservation structure reflects the categorisation and allocation approach disclosed for the issue, indicating the proportion of shares available to each investor segment.

Financial Health and Performance

Key Financial Metrics

  • Total Assets: Grew from ₹22.68 crore in FY24 to ₹45.57 crore as of Oct 2025.
  • Total income: Recorded at ₹36.93 crore in Oct 2025, as compared to ₹27.66 crore in FY24.
  • Profit After Tax (PAT): Reported at ₹6.06 crore in Oct 2025, and ₹2.93 crore in FY24.
  • Net Worth: Recorded at ₹36.47 crore in Oct 2025 in comparison to ₹15.06 crore in FY24.
  • Reserves & Surplus: Stood at ₹30.04 crore in Oct 2025, as compared to ₹9.95 crore in FY24.
  • Total Borrowing: Stood at ₹4.81 crore in Oct 2025, as compared to ₹2.86 crore in FY24.
  • EBITDA: Stood at ₹6.51 crore in Oct 2025 in comparison to ₹5.26 crore in FY24.

Recent Performance and Growth Prospects

  • The company’s asset base has expanded over the recent period, indicating an increase in scale of operations and resource deployment across its business segments.
  • Income levels have shown an upward movement, reflecting higher business activity and broader market reach across domestic and international operations.
  • Profitability has improved over the same period, suggesting changes in cost structures, operational efficiency, or product mix.
  • Net worth has increased, supported by internal accruals and retained earnings, which may influence the company’s financial position.
  • Growth in reserves and surplus indicates accumulation of earnings within the business, which may support future operational requirements.
  • Borrowings have also increased during the period, which may reflect funding requirements linked to business expansion and working capital needs.
  • EBITDA has shown an upward trend, indicating changes in operating performance before accounting for interest, tax, depreciation, and amortisation.
  • The overall financial trend reflects changes in scale, profitability, and capital structure, which may influence the company’s operational direction.

Investment Risks and Opportunities

Potential Risks of Investing in the IPO

  • The company’s operations depend on contract manufacturing partners and third-party sourcing, which may influence supply continuity, product availability, and quality control processes.
  • Expansion into international markets involves regulatory approvals and product registrations, which may affect timelines, compliance requirements, and market entry across different geographies.

Opportunities and Growth Potential

  • The company’s focus on speciality pharmaceutical formulations places it within a segment associated with demand for therapies targeting chronic and complex conditions across domestic and international markets.
  • Planned utilisation of IPO proceeds towards research and development, product registration, and marketing activities may support expansion of the product portfolio and geographic presence.

Key Performance Indicator (KPI)

KPI

Oct 31, 2025

Mar 31, 2025

ROE

18.11%

37.85%

ROCE

16.68%

33.39%

Debt/Equity

0.13

0.17

RoNW

16.61%

28.30%

PAT Margin

16.49%

14.77%

EBITDA Margin

17.73%

15.60%

Price to Book Value

2.19

2.62

Speciality Medicines Limited IPO Registrar & Lead Managers

Registrar

Lead Manager(s)

Skyline Financial Services Pvt.Ltd.

Unistone Capital Pvt.Ltd.

Company Address of Speciality Medicines Limited

913, One World West, S. No. 396, FP 119,

Village- Vejalpur, Ahmedabad City,

Ahmedabad, Gujarat, India,

Ahmedabad, Gujarat, 380051

Phone: +91 22 4604 5344

Email: investors.grievances@specialitymedicine.com

Website: https://www.specialitymedicine.com/

Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your Speciality Medicines IPO allotment status.

Frequently Asked Quetions

Who is the CEO of Speciality Medicines Ltd?

Parth Babulal Goyani is the Chairman and Managing Director of Speciality Medicines Ltd.

When will the Speciality Medicines IPO open for subscription?

The Speciality Medicines IPO is scheduled to open for subscription on 20 March 2026 and is set to close on 24 March 2026, as per the disclosed timeline.

What is the company’s core business, and how sustainable is its business model in the long term?

The company is engaged in the marketing and distribution of speciality pharmaceutical formulations used in treating chronic and complex conditions. Its business model includes contract manufacturing for international markets and distribution of sourced products domestically. The sustainability of this model depends on factors such as regulatory approvals, supplier relationships, product portfolio expansion, and demand for speciality therapies.

What is the issue size of the Speciality Medicines IPO?

The IPO comprises 23,50,000 shares with an aggregate issue size of up to ₹29 crore, based on the disclosed price band.

What is 'pre-apply' for the Speciality Medicines IPO?

‘Pre-apply’ refers to the facility that allows investors to submit their IPO application before the issue opens. The application is processed once the IPO subscription window begins, subject to mandate confirmation.

What is the lot size and minimum order quantity of the Speciality Medicines IPO?

The lot size for the IPO is 1000 shares. The minimum application for retail investors requires applying for at least two lots, which amounts to 2000 shares.

What is the allotment date for the Speciality Medicines IPO?

The tentative allotment date for the IPO is 25 March 2026, as per the provided schedule.

Who is the registrar of Speciality Medicines IPO?

The registrar to the issue is Skyline Financial Services Pvt. Ltd., responsible for handling the allotment and related processes.

Are there any governance issues or red flags in the company’s leadership or board structure?

There are no publicly stated governance issues or red flags highlighted. Investors may review the offer documents, including sections on management, board composition, and risk factors, for detailed and verified disclosures.

What is the process to apply for the Speciality Medicines IPO?

The application process can be completed through the ASBA facility via net banking or through a UPI-enabled trading platform. Investors are required to select the IPO, enter bid details such as price and quantity, and approve the payment mandate within the specified timeline.

Do I need a Demat account to apply for the Speciality Medicines IPO?

Yes, a Demat account is required to apply for the IPO, as shares are credited in electronic form upon allotment.

How will I know if my application for the Speciality Medicines IPO has been successful?

After the allotment process is completed, applicants can check their allotment status through the registrar’s website or the trading platform used for application. If shares are allotted, they are credited to the Demat account, and any unallocated amount is released as per the applicable process.

Published Date : 23 Mar 2026

Disclaimer :

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.


The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.



Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 lakh+ Users

icon-with-text

4.7 App Rating

icon-with-text

4 Languages

icon-with-text

₹7,300+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|